Month: December 2015

December 28, 2015, by NCI Staff Last month, the FDA approved two drugs that inhibit the activity of the epidermal growth factor receptor, or EGFR, for the treatment of patients with advanced lung cancer. Credit: Wikimedia Commons Last month, the Food and Drug Administration (FDA) approved two targeted therapies for patients with advanced non-small cell
0 Comments
December 23, 2015, by NCI Staff A new study highlights the importance of discussions between patients and their physicians about the costs of cancer care. Credit: iStock In a survey of cancer survivors, many reported having experienced financial difficulties—such as going into debt, filing for bankruptcy, and consistent worry about financial issues—related to their disease
0 Comments
December 22, 2015, by NCI Staff NCI’s SEER program recently released the newest installment in its Did You Know video series. Many other new resources are available from NCI. NCI is constantly publishing new information on its websites, so periodically we provide updates on new content of interest to the cancer community. Email Subscription Service
0 Comments
December 18, 2015, by NCI Staff NCI’s Dr. James Gulley (left) talks with his patient being treated at the NIH Clinical Center. Credit: NIH Intramural Research Program Earlier this year, former U.S. President Jimmy Carter announced that he was undergoing treatment for advanced melanoma that included the immunotherapy drug pembrolizumab (Keytruda®)—part of a class of
0 Comments
December 17, 2015, by NCI Staff Image of neuroblastoma cells, the most common solid cancer found in children younger than age 5. Credit: The Cell Image Library / CC BY 3.0 An international team of scientists has identified a possible new treatment target for pediatric neuroblastoma. Based on promising findings in animal models, the team
0 Comments
December 15, 2015, by NCI Staff Cobimetinib inhibits the activity of an enzyme known as MEK and vemurafenib inhibits the enzyme BRAF to disrupt cancer cell growth and survival. Credit: Cisbio Bioassays On November 10, the Food and Drug Administration (FDA) approved the use of cobimetinib (Cotellic™) in combination with vemurafenib (Zelboraf®) to treat patients
0 Comments
When walking you need your shoes to handle that repetitive heel-to-toe rolling motion. After all, “a 150-pound woman’s body encounters between 900,000 and 1,350,00 pounds of impact over a three-mile walk,” says Paul Langer, DPM, author of Great Feet for Life. So make sure your kicks are comfy and supportive—a poor fit can lead to
0 Comments
  With 2016 on the horizon, that means another 365 days to get your sweat on (minus a few rest and recovery days, of course). Curious what trends are on tap? Here are the top five (and then some) according to the American College of Sports Medicine’s (ACSM) annual survey, which was completed by more than
0 Comments
December 4, 2015, by NCI Staff Soft tissue sarcoma forms in soft tissues of the body, including muscle, tendons, fat, blood vessels, lymph vessels, nerves, and tissue around joints. On October 23, the Food and Drug Administration (FDA) approved trabectedin (Yondelis®) for the treatment of two subtypes of soft tissue sarcomas: liposarcoma and leiomyosarcoma. The
0 Comments